Mobile

Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®

Update Il y a 5 ans
Reference: EUCTR2009-012270-12

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine reversibility of eGFRMDRD decrease following 52 weeks of 150 μg aleglitazar treatment and 8 weeks follow up observation after the last study medication, in patients with T2D and moderate renal function impairment (CKD stage 3), in comparison with Actos® treatment.

Inclusion criteria

  • Type 2 diabetes with moderate renal function impairment

Links